[6] In the last decade, a growing body of evidence supports the NfL as a biomarker of brain injury or neurodegeneration in CSF and blood in a variety of neurological disorders, which may have clinical promise.[7] However, previous studies on NfL concentration in PD were inconsistent. The gene discussed is NEFL; the disease is Parkinson disease.